Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Top Cited Papers
- 11 July 2019
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 381 (2), 121-131
- https://doi.org/10.1056/nejmoa1903835
Abstract
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer.Keywords
Funding Information
- Canadian Cancer Society (704970)
- Cancer Australia (Support for Cancer Clinical Trials Program)
- National Health and Medical Research Council (Practitioner Fellowship APP1102604, Program Grants 1037786 and 1150467)
- Astellas Scientific and Medical Affairs
This publication has 20 references indexed in Scilit:
- Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancerAnnals of Oncology, 2018
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialJournal of Clinical Oncology, 2018
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 StudiesEuropean Urology, 2018
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerThe New England Journal of Medicine, 2017
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyThe New England Journal of Medicine, 2017
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 TrialEuropean Urology, 2016
- Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataThe Lancet Oncology, 2015
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2015
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerThe New England Journal of Medicine, 2015
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013